000157423 001__ 157423
000157423 005__ 20240229133507.0
000157423 0247_ $$2doi$$a10.1093/jnci/djaa099
000157423 0247_ $$2pmid$$apmid:32766851
000157423 0247_ $$2ISSN$$a0027-8874
000157423 0247_ $$2ISSN$$a0198-0157
000157423 0247_ $$2ISSN$$a1460-2105
000157423 0247_ $$2altmetric$$aaltmetric:87951987
000157423 037__ $$aDKFZ-2020-01618
000157423 041__ $$aeng
000157423 082__ $$a610
000157423 1001_ $$aLee, Alice W$$b0
000157423 245__ $$aExpanding our understanding of ovarian cancer risk: the role of incomplete pregnancies.
000157423 260__ $$aOxford$$bOxford Univ. Press$$c2021
000157423 3367_ $$2DRIVER$$aarticle
000157423 3367_ $$2DataCite$$aOutput Types/Journal article
000157423 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1617968081_17265
000157423 3367_ $$2BibTeX$$aARTICLE
000157423 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157423 3367_ $$00$$2EndNote$$aJournal Article
000157423 500__ $$a2021 Mar 1;113(3):301-308
000157423 520__ $$aParity is associated with decreased risk of invasive ovarian cancer; however, the relationship between incomplete pregnancies and invasive ovarian cancer risk is unclear. This relationship was examined using 15 case-control studies from the Ovarian Cancer Association Consortium (OCAC). Histotype-specific associations, which have not been examined previously with large sample sizes, were also evaluated.A pooled analysis of 10,470 invasive epithelial ovarian cancer cases and 16,942 controls was conducted. Odds ratios and 95% confidence intervals for the association between incomplete pregnancies and invasive epithelial ovarian cancer were estimated using logistic regression. All models were conditioned on OCAC study, race/ethnicity, age, and education level, and adjusted for number of complete pregnancies, oral contraceptive use, and history of breastfeeding. The same approach was used for histotype-specific analyses.Ever having an incomplete pregnancy was associated with a 16% reduction in ovarian cancer risk (OR = 0.84, 95% CI = 0.79 to 0.89). There was a trend of decreasing risk with increasing number of incomplete pregnancies (two-sided Ptrend <.001). An inverse association was observed for all major histotypes; it was strongest for clear cell ovarian cancer.Incomplete pregnancies are associated with a reduced risk of invasive epithelial ovarian cancer. Pregnancy, including incomplete pregnancy, was associated with a greater reduction in risk of clear cell ovarian cancer, but the result was broadly consistent across histotypes. Future work should focus on understanding the mechanisms underlying this reduced risk.
000157423 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000157423 588__ $$aDataset connected to CrossRef, PubMed,
000157423 7001_ $$aRosenzweig, Stacey$$b1
000157423 7001_ $$aWiensch, Ashley$$b2
000157423 7001_ $$aGroup, Australian Ovarian Cancer Study$$b3$$eCollaboration Author
000157423 7001_ $$aRamus, Susan J$$b4
000157423 7001_ $$aMenon, Usha$$b5
000157423 7001_ $$aGentry-Maharaj, Aleksandra$$b6
000157423 7001_ $$aZiogas, Argyrios$$b7
000157423 7001_ $$aAnton-Culver, Hoda$$b8
000157423 7001_ $$aWhittemore, Alice S$$b9
000157423 7001_ $$aSieh, Weiva$$b10
000157423 7001_ $$aRothstein, Joseph H$$b11
000157423 7001_ $$aMcGuire, Valerie$$b12
000157423 7001_ $$aWentzensen, Nicolas$$b13
000157423 7001_ $$aBandera, Elisa V$$b14
000157423 7001_ $$aQin, Bo$$b15
000157423 7001_ $$aTerry, Kathryn L$$b16
000157423 7001_ $$aCramer, Daniel W$$b17
000157423 7001_ $$aTitus, Linda$$b18
000157423 7001_ $$aSchildkraut, Joellen M$$b19
000157423 7001_ $$aBerchuck, Andrew$$b20
000157423 7001_ $$aGoode, Ellen L$$b21
000157423 7001_ $$aKjaer, Susanne K$$b22
000157423 7001_ $$aJensen, Allan$$b23
000157423 7001_ $$aJordan, Susan J$$b24
000157423 7001_ $$aNess, Roberta B$$b25
000157423 7001_ $$aModugno, Francesmary$$b26
000157423 7001_ $$aMoysich, Kirsten$$b27
000157423 7001_ $$aThompson, Pamela J$$b28
000157423 7001_ $$aGoodman, Marc T$$b29
000157423 7001_ $$aCarney, Michael E$$b30
000157423 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b31$$udkfz
000157423 7001_ $$aRossing, Mary Anne$$b32
000157423 7001_ $$aHarris, Holly R$$b33
000157423 7001_ $$aDoherty, Jennifer Anne$$b34
000157423 7001_ $$aRisch, Harvey A$$b35
000157423 7001_ $$aKhoja, Lilah$$b36
000157423 7001_ $$aAlimujiang, Aliya$$b37
000157423 7001_ $$aPhung, Minh Tung$$b38
000157423 7001_ $$aBrieger, Katharine$$b39
000157423 7001_ $$aMukherjee, Bhramar$$b40
000157423 7001_ $$aPharoah, Paul D P$$b41
000157423 7001_ $$aWu, Anna H$$b42
000157423 7001_ $$aPike, Malcolm C$$b43
000157423 7001_ $$aWebb, Penelope M$$b44
000157423 7001_ $$aPearce, Celeste Leigh$$b45
000157423 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djaa099$$gp. djaa099$$n3$$p301-308$$tJournal of the National Cancer Institute$$v113$$x1460-2105$$y2021
000157423 909CO $$ooai:inrepo02.dkfz.de:157423$$pVDB
000157423 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b31$$kDKFZ
000157423 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157423 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000157423 9141_ $$y2021
000157423 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-01-09$$wger
000157423 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2018$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-09
000157423 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2018$$d2020-01-09
000157423 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000157423 980__ $$ajournal
000157423 980__ $$aVDB
000157423 980__ $$aI:(DE-He78)C020-20160331
000157423 980__ $$aUNRESTRICTED